Vimarsana
Biggest News Aggregation in the World

Aldafermin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aldafermin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aldafermin Today - Breaking & Trending Today

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023 - Vimarsana News

NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023

Aldafermin demonstrated statistically significant reductions in serum 7αC4 and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-DAround 25-50% of patients with... | May 8, 2023

NGM Bio's NASH drug fails in Phase 2; focus shifts to Merck-partnered programs - Vimarsana News

NGM Bio's NASH drug fails in Phase 2; focus shifts to Merck-partnered programs

An NGM Biopharmaceuticals drug candidate for the fatty liver disease NASH failed a Phase 2b study less than a year after the company reported positive results from an earlier mid-stage study. The biotech will now focus on programs in eye diseases and cancer that are partnered with Merck.